Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_assertion type Assertion NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_head.
- NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_assertion description "[Similar as tunicamycin, treatment with RES lead to the activation of all 3 branches of the UPR, with early splicing of XBP-1 indicative of IRE1 activation, phosphorylation of eIF2alpha consistent with ER resident kinase (PERK) activation, activating transcription factor 6 (ATF6) splicing, and increase in expression levels of the downstream molecules GRP78/BiP, GRP94 and CHOP/GADD153 in human Burkitt's lymphoma Raji and Daudi cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_provenance.
- NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_assertion evidence source_evidence_literature NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_provenance.
- NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_assertion SIO_000772 20723265 NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_provenance.
- NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_assertion wasDerivedFrom befree-2016 NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_provenance.
- NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_assertion wasGeneratedBy ECO_0000203 NP833786.RAoRxYW71JE4ACUh3bsf6gSc9c1h_i0kftMxeAgxqr3iQ130_provenance.